; Summary: We determined the optimal conditions for the Separation of N-glycosylation variants of prostate-specific : antigen using concanavalin A. Concanavalin A is a lectin that binds to the terminal sugar residues of glycoproteins. We demonstrated that differences in the percentage of prostate-specific antigen bound to concanavalin A-Sepharose in patients with benign prostatic hyperplasia compared with patients with prostatic carcinoma, s described in the literature, arise when insufficient concanavalin A binding sites are added for complete binding of the glycosylation ' variants of prostate-specific antigen.
. , . tnbution of the concanavalin A non-reactive fraction of the cytoplasm of both benign and malignant prostate n τ* . · -CL -^ *UT"-U-J + * prostate-specific antigen for benign prostatic hyperplasia cells. Its unique organ specificity established prostate-* K 6 .
^.fl : specific antigen s the most sensitive marker of prostatic and P rostate cancer P^ents D.fferent procedures were cancer. However, benign prostatic hyperplasia, a com-used in these stud.es. Marrmfr et al. (5) recently reported mon condition in elderly, is also associated with a slight that there 1S no «nfang diffewice m the glycosylahon elevation of the prostate-specific antigen concentration P attern of Prostate-spec.fic an gen m bemgn or mahg-/j 2\ nant prostate disease and that any binding ratio can be found. We indicated that the conclusions might be influBarak et al. (3) observed different N-glycosylation vari-enced by Λβ experimental conditions used, like insufants of prostate-specific antigen in patients with benign ficient corree tion for dilution effects (6). prostatic hyperplasia compared with patients with carcinoma of the prostate. The authors presented a complete Changes in the N-glycosylation of proteins in cancer and differentiation of benign prostatic hyperplasia and pros-their investigation using lectins have recently been extate cancer patients on the basis of percentages of pros-tensively reviewed (7) . It is clear that differences in glytate-specific antigen bound to concanavalin A-Se-cosylation could provide the basis for more sensitive and more discriminative clinical tests. However, it should be realised that the non-covalent lectin-carbohydrate interactions will be influenced by various experimental variables and therefore the search for optimal assay conditions is of utmost iraportance.
Here, we determined the optimal conditions for Separation of the molecular variants of prostate-specific antigen using concanavalin A-Sepharose. We examined discrepancies in the literature concerning differences in the N-glycosylation of prostate-specific antigen variants in patients with benign prostatic hyperplasia and patients with cancer of the prostate.
Materials and Methods

Subjects and specimens
Blood specimens were collected from males attending the Urology Department of De Wever Hospital in Heerlen (NL) with the presumptive diagnosis of carcinoma of the prostate. Specimens were collected betöre rectal examination. The diagnosis of prostate cancer was established histologically, whereas the diagnosis of benign prostatic hyperplasia was made on a clinical basis (history, rectal palpation, endoscopy). Bone metastases were established by bone scan. The cancer group was classified according to the TNM system of the Union International Contre le Cancer. Sera of 16 prostatic cancer patients (untreated) and 77 patients with benign prostatic hypertrophy were frozen at -20 °C. Patients with prostatespecific antigen concentration below 15 g/l were not included in the comparative study, because reliable analysis of the fraction of prostate-specific antigen bound to concanavalin A-Sepharose is not possible (see results section).
Methods
Concanavalin A-Sepharose (100 ml, code 17-0440-01, Pharmacia, Woerden, NL) or Sepharose CL-4B (100 ml, code 17-0150-01, Pharmacia) was washed five times with 100 ml buffer (0.5 mol/1 NaCl, l mmol/1 MnCl 2 , l mmol/1 MgCl 2 and l mmol/1 CaCl 2 and 0.1 mol/1 sodium acetate buffer, pH 6.5) and the remaining concanavalin A-Sepharose, after suction over a Whatman (GF/D) filter, was suspended in 75 ml buffer. Varying amounts of concanavalin A-Sepharose or Sepharose 4B were pipetted into tubes and the supernatant was removed after centrifugation for 10 min at 6000 min"
1 . The volüme of the remaining swollen gel was determined (4ml contained 2.8 ml completely swolien gel; the completely swollen gel contained about 6.8 gram dry concanavalin A-Sepharose per 100 ml). After adding serum or diluted serum to the completely swollen gel, the mixture was incubated at room ten> perature for 2 hours with gentle sh^king on an overhead rotator and centrifuged äs indicated before. Ine supernatant was aspirated for analysis of prostate-specific antigen and albumin.
Prostate-specific antigen was determined on a Stratus analyser (Baxter, Maarssen, NL) using a Fluorometric Enzyme Immunoassay (Hybritech, Ely Lilly, Nieuwegein, NL). Dilutions were performed with the High Sample Diluent (büffer solution eontaining bovine serum albumin) in the testkit.
Albumin was determined on a Cobas Fara analyser (Röche, Mijdrecht, NL) using the bromocresol green method (Instruchemie, Hilversum, NL).
Statistical analysis
A paired Student's t-test was used for compärison of the results.
Results and Discussion
Optimization of the method
Correction for serum dilution by addition of swollen concanavalin A-Sepharose
Pre-diluted samples of 0.5 ml from a patient with malignant prostatic disease (prostate-specific antigen 1235 §/1, diluted 25 times with diluent before incubation), were incubated with varying amounts (0.15; 0.3; 0.6; 1.2; 2.4 ml) of completely swollen concanavalin A^Se-pharose of Sepharose 4B. Barak et al. (3) used a separate experiment with Sepharose 4B to correct for the dilution introduced by adding the concanavalin A-Sepharose. The glycosylation variants of prostate-specifie antigen do not bind to Sepharose 4B; the fraction of non-binding prostate-specific antigen was calculated äs follows:
% non-bound prostate-specific antigen = 100 X prostate-specific antigen in serum treated with concanavalin A-Sepharose prostate-specific antigen in serum treated with Sepharose 4B
From figure l it can be concluded that albumin (nonglycosylated protein) does bind to -concanavalin A-Sepharose or to Sepharose 4B. The dilution of serum caused by addition of concanavalin A-Sepharose was also determined by measuring the serum albumin concentration before and after addition of concanavalin ASepharose. Experimental error is smaller when the dilution factor is obtained this way, rather than by performing a separate experiment with Sepharose 4B. Therefore, we used the dilution of serum albumin to correct for the dilution caused by addition of swollen gel.
% non-bound prostate-specific antigen prostate-specific antigen in serum treated with concanavalin A-Sepharose = 100 X *L diiution factor. prostate-specific antigen in serum Dilution factor = albumin in serum albumin in serum treated with concanavalin A-Sepharose Prostate-specific antigen bound to concanavalin A-Sepharose (%) = 100 -prostate-specific antigen non-bound (%).
Effect of serum prolein concentration on binding of prostate-specific antigen to concanavalin A-Sepharose
A serum sample with a prostate-specific antigen concentration of 3250 g/l was pre-diluted with a nil serum (serum containing no prostate-specific antigen) or with diluent (containing bovine serum albumin, a non-glycoprotein). Pre-dilution with the diluent dirainishes the glycoprotein concentration of the sample. As can be seen in figure 2, optimal binding is obtained at a much lower concanavalin A concentration for samples pre-diluted with diluent than for samples pre-diluted with the nil {serum. For measurements in serum (diluted with nil j serum) at least 2.5 ml completely swollen concanavalin | A-Sepharose is required to allow optimal binding of | prostate-specific antigen, e. g. to reach a Situation where i binding is independent of the serum glycoprotein concentration. As concanavalin A binding sites are also occupied by other glycoproteins in the serum sample, fewer concanavalin A binding places are required when using sera pre-diluted with the diluent. Figure 2 shows that for undiluted serum samples at least 2.5 ml completely swollen gel is required to provide sufficient concanavalin A binding sites. When sub-optimal concanav- Fig. 1 . Samples (0.5 inl) from a patient with maligjiant prostatic disease (prostate-specific antigen: 1235 ^ , pre-diluted 25 times with diluent) were incubated with increasing amounts of completely swollen 5 Sephärose 4B (·) or concanavalin A-Sepharose («); the supematant was removed after centrifugation. The ratio, i. e. the conceittiration non-bound to Sephärose or to concanavalin ArSepharose in the supematant (c s upematant) divided by the original sample eoncentration (c or jg inQ i serum) is depicted for both the non-glycosylated protein albumin ( -) and for the glycosyiated protein prostate-specific antigen (-). alin A binding sites are available, pre-diluted samples (samples with high prostate-specific antigen concentrations, mostly patients with carcinoma of the prostate) may give higher binding percentages than samples from benign prostatic hyperplasia patients, containing less prostate-specific antigen and needing no pre-dilution. This might erroneously suggest differences in the glycosylation pattera of prostate-specific antigen for patients with benign prostatic hyperplasia compared with patients with carcinoma of the prostate. Figure 3 presents the binding curves for three serum specirnens of prostate carcinoma patients with different prostate-specific antigen concentrations. For all three specirnens the optimal amount of concanavalin A-Sepharose appeared to be at least 2.8 ml of completely swollen gel. Neither Barak et al. (3) nor Chan & Gao (4), who advocated the use of concanavalin A binding to prostate-specific antigen to discriminate between patients with benign prostatic hyperplasia or prostatic carcinoma, described control experiments to investigate whether sufficient concanavalin A binding sites were present during their experiments. From our experiments it can be concluded that with 0.5 ml undiluted serum, at least 2.5 ml completely swollen concanavalin A-Sepharose should be used to obtain maximal binding of To ensure maximal binding at least 2.5 ml completely swollen concanavalin A-Sepharose is required for 0.5 ml serum (undiluted).
the glycosylation variants of prostate-specific antigen. Moreover, a correction should be made for the dilution of serum due to the addition of gel (see fig. 1 ). Both Barak et al. (3) and Chan & Gao (4) used a l : l ratio of serum to concanavalin A-Sepharose, which probably leads to the addition of insufficient binding sites ( fig. 3 ).
The optimized procedure for measuring patient samples therefore is: Serum (0.5 ml, not pre-diluted) is added to 2.8 ml completely swollen concanavalin A-Sepharose. After adding serum to the gel the mixture is incubated at room temperature for 2 hours with gentle shaking on an overhead rotator and subsequently centriftiged. The supernatant is aspirated for analysis of prostate-specific antigen and albumin, from which a correction for dilution can be made; see the calculation of the percentage prostatespecific antigen bound to concanavalin A-Sepharose (above).
To allow comparison with other studies, we also analysed the samples with the sub-optimal procedure. Here, 0.5 ml serum (not pre-diluted) is added to 0.5 ml completely swollen concanavalin A-Sepharose. The final part of the procedure is similar to the optimized procedure described above.
Precision
The detection limit of the prostate-specific antigen determination is 0.24 μ §/1, which implies that for the optimized procedure (2.8 ml swollen gel and 0.5 ml serum) at -0%, 90% and 95% binding, the theoretical minimal serum concentration for detection of prostate-specific antigen in the supernatant after incubation with the gel should be respectively 1.3, 13.0 and 25.9 μg/l prostatespecific antigen. This indicates that in this procedure, for binding percentages of 90%, sera should theoretical contain at least 13 μg/l prostate-specific antigen.
; r Precision was determined by measuring the percentage of concanavalin A-Sepharose binding for three sera with different prostate-specific antigen concentrations. For each serum the percentage prostate^specific antigen bound was determined from ten separate binding experiments. For each experiment 0.5 ml serum was added to 2.8 ml of completely swollen gel. Mean serum prostatespecific antigen concentrations were 12.2, 33.8 and 83.7 μg/l and the percentages bound to concanavalin A-Sepharose were respectively 73.7 ± 16.3%; 86.9 ± 3.3% and 87.4 ± 2.3% (mean +: CV). A large experimental error is observed for the samples with serum prostatespecific antigen concentrations lower than 15 μ^Ι, especially when high percentage binding of prostatespecific antigen to concanavalin A-Sepharose is expected. Assay variations were not giVefi in earlier studies on this subject.
For a sample containing 15 μ£/1, addition of concanavalin A results in a decrease of prostate-specific antigen to less than 3 μg/l prostate-specific antigen. When 80-90% of the prostate-specific antigen binds to the concanavalin A, s can be expected, concentrations below 0.3 \ig/\ prostate-specific antigen have to be detected. Therefore these experiments cannot be performed on samples with prostate-specific antigen concentrations below 15 μ §/1, because the assay Variation becomes too large. This makes the method unsuitable for discrimination of benign prostatic hyperplasia and carcinoma patients with prostate-specific antigen concentrations below 15 μ §/1.
Tab. l Comparison of the optimal (2.8 ml swollen coneanavalin A-Sepharose) and the sub-optimal (0.5 ml swollen concanavalin A-Sepharose) bindiag assay used to separate the glycosylation variants of prostate-specific antigen in patients with benign prostatic hyperplasia or carcinoma of the prostate. Patients with prostate-specific antigen concentrations below 15 μg/l were eleminated froin the study, because reliable analysis of the percentage prostate-specific antigen bound to concanavalin A-Sepharose is not possible. Therefore only 7 benign prostatic hyperplasia (52.8 ± 50. l μg/l prostate-specific antigen, mean ± SD) and 14 prostatic carcinoma patients (1280 ± 4130 μg/l prostate-specific antigen, mean ± SD) were included in the comparative study. The prostate-specific antigen concentrations of the two carcinoma patients eliminated were respectively 8.9 and 13.9 μ §/1. The mean prostatespecific antigen concentration of the 72 benign prostatic hyperplasia patients with prostate-specific antigen concentrations lower than 15 μg/l, that were not included in the comparative study, was 2,9 ± 2.5 μg/l (mean ± SD). Figure 4 presents the distribution of the percentages of ; concanavalin A-Sepharose-bound prostate-specific anti-1 gen in prostatic cancer and in benign prostatic hyperplasia patients. Sera (0.5 ml) from prostate cancer patients and from benign prostatic hyperplasia patients were treated with 2.8 ml completely swollen concanava-1 lin A-Sepharose. To allow comparison with earlier studi ies, all samples were also measured under sub-optimal binding conditions, where 0.5 ml serum was added to 0.5 ml completely swollen concanavalin A-Sepharose. The percentage prostate-specific antigen bound to concanavalin A-Sepharose was determined s described earlier. Benign, prostate Prostate cancer hyperplasia Fig. 4 Distribution of the percentage of prostate-specific antigen bound to concanavalin A-Sepharose in patients with prostate cancer (14) or benign prostate hypeipl sia (7) having prostate-specific antigen concentrations higher than 15 pg/l. Both the optimal binding assay (2.8 ml concanavalin A-Sepharose (O)) and the sub-optimal binding assay (0.5 ml concanavalin ASepharose (o)) were used.
With the optimized procedure (2.8 ml concanavalin ASepharose) no significant differences in prostate-specific antigen glycosylation patterns were observed between benign prostatic hyperplasia and prostatic carcinoma patients. The sub-optimal procedure also showed no significant differences between benign prostatic hyperplasia and carcinoma patients. since different pre-treatments can lead to results that glycosylation between benign prostatic hyperplasia and prostate carcinoma patients, all samples underwent the same pre-treatment, i. e. no difference in the pre-dilution of samples from carcinoma patients and benign prostatic hyperplasia patients. Highly significant differences (p < 0.0001) were found with the optimal binding assay (2.8 ml concanavalin ASepharose) but not with the sub-optimal binding assay (0.5 ml concanavalin A-Sepharose).
From the data presented we suggest that the discrepancies in the literature are probably caused by the use of insufficient concanavalin A binding capacity (3, 4) , the lack of correction (4), or incorrect evaluation of the dilution effect caused by addition of concanavalin A-Sepharose (5) or pre-dilution of samples with high prostate-specific antigen concentrations (carcinoma group), in contrast to the samples of patients with benign prostatic hyperplasia. Moreover, none of the studies report the lower detection limit or the analytical Variation, especially for prostate-specific antigen concentrations below 15 μ §/1, where an extremely large experimental error is to be expected when the percentage of prostatespecific antigen bound to concanavalin A-Sepharose is higher than 90%.
From the results we conclude that when using optimal binding conditions (i. e. maximal binding of N-glycosylation variants of prostate-specific antigen to concanavalin A-Sepharose and no pre-dilution of samples with high prostate-specific antigen concentrations), no significant differences in binding ratio can be demonstrated between patients with benign prostatic hyperplasia and patients with prostatic carcinoma.
In general, there is a danger of drawing invalid conclusions from measurement of the lectin binding of glycoproteins in serum, since non-covalent lectin-carbohydrate interactions are influenced by a number of different experimental variables.
